-
FDA одобрило новый генетический тест
-
Очередной номер журнала "Фармакогенетика и фармакогеномика"
-
Zastrozhin MS., Sorokin AS., Agibalova AV., et al. Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers Human Psychopharmacology: Clin
-
Sychev D, Shikh N, Morozova T, et al. Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension. Pharmacogenomics and Personalized Medicine 2018, 11:157-165.
-
Zastrozhin MS, Antonenko AP, Nesterenko EV, et al. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. Drug Metab Pers Ther. 2018 Oct
